Main Street Group’s TG Therapeutics TGTX Stock Holding History

Main Street Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.1K	Hold	621	–	–	0.01%	333
2026 Q1	$20.6K	Buy	+621	New	+$18.5K	0.01%	438
2025 Q4	–	Sell	-160	Closed	-$5.78K	–	545
2025 Q3	$5.78K	Hold	160	–	–	﹤0.01%	594
2025 Q2	$5.76K	Hold	160	–	–	﹤0.01%	566
2025 Q1	$6.31K	Hold	160	–	–	﹤0.01%	562
2024 Q4	$4.82K	Buy	+160	New	+$4.59K	﹤0.01%	596

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Main Street Group's TGTX Position: Q2 2026 in Review

Main Street Group held its TG Therapeutics (TGTX) position steady in Q2 2026 at 621 shares worth $34.1K. The position accounts for 0.01% of the portfolio, ranked #333.

Main Street Group first reported a position in TGTX in Q4 2024 and has held it in 6 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Main Street Group held 621 shares of TG Therapeutics worth $34.1K as of Q2 2026.
Main Street Group left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.01% of Main Street Group's portfolio in Q2 2026, its #333 holding.
Main Street Group first reported a position in TG Therapeutics in Q4 2024 and has held it in 6 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Main Street Group's 13F filing for Q2 2026, filed 13 Jul 2026.